Anahita Ahmadsina - NourDanesh Institute of Higher Education, Meymeh, Isfahan, Iran
Kamran Ghaedi - Cellular and Molecular Biology Division, Biology Department, Faculty of Sciences, University of Isfahan, Isfahan, Iran
Mansoureh Azadeh - Zistfanavari biotechnology institute, Isfahan, Iran
Atefeh Zamani - Zistfanavari biotechnology institute, Isfahan, Iran

Breast cancer is a complex disease caused by the progressive accumulation of multiple gene mutations combined with epigenetic dysregulation of critical genes and protein pathways. The discovery that mutations in the BRCA1 and BRCA2 genes increase the risk of breast cancers has radically transformed our understanding of the genetic basis of breast cancer, leading to improved management of high-risk women. Genomic changes differentiate tumors from normal tissues, permitting targeted treatments for several types of tumor and thereby extending survival and improving patients’ quality of life. According to the U.S. National Institutes of Health (NIH), personalized medicine is an emerging practice of medicine that uses an individual s genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease . The immediate challenge is to learn how to use the molecular characteristics of an individual and their tumor to improve detection and treatment, and ultimately to prevent the development of breast cancer. Personalized medicine builds on the Human Genome Project, which was forecasted to revolutionize disease risk prediction, with projected relative risks. The ultimate goal of personalized medicine is to furnish the proper treatment to the right person at the right time. Based on articles by google scholar, pubmed and science direct, we got these results. Personalized medicine is receiving a large amount of growing attention for its tremendous potential with myriad new opportunities. The ultimate promise of personalized medicine depends on the discovery of the personal genetic causes of disease.

Personalized medicine; Breast cancer; BRCA1; BRCA2; Treatment; Human Genome Project